

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/11081 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/US00/21340**

(22) International Filing Date: 4 August 2000 (04.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/147,551 6 August 1999 (06.08.1999) US

(71) Applicant (for all designated States except US): IVI-GENE CORPORATION [US/US]; 12085 Research Drive, Alachua, FL 32615 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PROGULSKE-FOX, Ann [US/US]; 6392 Country Road 214 S, Keystone Heights, FL 32656 (US). HANDFIELD, Martin [CA/US]; 2001 SW 16th Street #E-5, Gainesville, FL 32608 (US). BRADY, L., Jeannine [US/US]; 13214 NW County Rd. 231, Gainesville, FL 32609 (US). HILLMAN, Jeffrey, D. [US/US]; 6424 SW 26th Place, Gainesville, FL 32608 (US).

(74) Agent: HILLMAN, Lisa; McDonnell Boehnen Hulbert & Berghoff, 32nd floor, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/11081 A2

(54) Title: MICROBIAL POLYNUCLEOTIDES EXPRESSED DURING INFECTION OF A HOST

(57) Abstract: The invention provides methods useful for identifying polynucleotides expressed *in vivo* by a microbe during infection of a host. Antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro* are adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Unadsorbed antibodies are isolated and are probed against an expression library of the microbe's DNA. A polynucleotide of the microbe that is expressed *in vivo* is isolated and identified.

**MICROBIAL POLYNUCLEOTIDES EXPRESSED
DURING INFECTION OF A HOST**

5

GOVERNMENT INTERESTS

This invention was made with Government support under Grant Number DE11857 awarded by the National Institute of Dental and Craniofacial Research. The Government has certain rights in the invention.

10

PRIORITY

This application claims priority from provisional application 60/147,551, filed August 6, 1999, which is herein incorporated by reference.

TECHNICAL AREA OF THE INVENTION

This invention provides methods and compositions for identifying and obtaining 15 microbial polynucleotides expressed during infection of a host and the use of these polynucleotides in the diagnosis, treatment, and prevention of microbial infections.

BACKGROUND OF THE INVENTION

Microbial infections are complex, dynamic processes that evolve constantly within the host. In many instances, virulence gene expression is modulated in response to the changing 20 environment encountered at the site of infection. Mekalanos, *J. Bacteriol.* 174:1-7 (1992); Mahan *et al. Science* 259:686-688 (1993). It is unlikely that all regulated virulence determinants of a pathogen can be identified *in vitro* because it is technically impossible to determine and mimic all of the complex and changing environmental stimuli that occur at the site of an

infection. Pioneering technologies such as *in vivo* expression technology (IVET), signature-tagged mutagenesis (STM) and differential fluorescence induction (DFI) were designed to identify genes specifically expressed *in vivo*, and fill the gaps in our understanding of microbial pathogenesis. Handfield & Levesque, *FEMS Microbiol. Rev.* 23:69-91 (1999); Heithoff *et al.*,
5 *Trends Microbiol.* 5:509-513 (1997); Chiang *et al.*, *Ann. Rev. Microbiol.* 53:129-154 (1999); Hautefort & Hinton, *Phil. Trans. R. Soc. London Ser. B*, 255:601-611 (2000). All of these methods depend on a reasonable assumption: namely, that genes which are specifically induced during *in vivo* growth are likely to be important to the pathogenic process.

Although remarkably powerful, all of these technologies have certain limitations. Their
10 major drawback is that they depend on the use of animal models of infection; animal models are not available for many pathogens and, in those cases where an animal model is available, it might not closely approximate the human condition. Consequently, a number of examples exist in the literature of erroneous conclusions being drawn by extrapolation of results from animal models to human infections. Smith, *Trends Microbiol.* 6:239-243 (1998). Further, many of these
15 schemes are not readily applicable to genetically "undomesticated" microbes, that is microbes for which there is no well established or reliable means for genetic manipulation. Additionally, IVET, STM, and related technologies are technically difficult, and therefore restrict analysis to a single representative strain of the microbe and to only one or several time points in the infection process.

20 An example of a microbe that is not easily characterized by IVET, STM, and related technologies is *Actinobacillus actinomycetemcomitans* (*Aa*), an etiologic agent of periodontal diseases. *Aa* has emerged as one of the best examples of a bacterium demonstrating a direct correlation with disease manifestation in the oral cavity. *Aa* is known to be the etiologic agent

for localized juvenile periodontitis (LJP). See, Slots & Ting, *Periodontol.* 2000, 20:82-121 (1999). Despite the fact that some *Aa* virulence factors have been identified, other important contributors to the infectious process have yet to be identified.

SUMMARY OF THE INVENTION

5 It is an object of the invention to provide methods for identifying polynucleotides useful for vaccine design, diagnostics, and antibiotherapy. It is a further object of the invention to provide methods and compositions useful in vaccine design, diagnosis, and therapy of *A. actinomycetemcomitans* infection. This and other objects of the invention are provided by one or more of the embodiments described below.

10 The invention provides methods useful for identifying polynucleotides expressed by a microbe during infection of a host. One embodiment provides a method of identifying a polynucleotide of a microbe that is expressed *in vivo*. Antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro* are adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Unadsorbed antibodies are isolated and are probed 15 against an expression library of the microbe's DNA or RNA. A polynucleotide of the microbe that is expressed *in vivo* is isolated and identified.

Another embodiment of the invention provides a method of comparing polynucleotides of a microbe that are expressed *in vivo* at different stages of infection of the microbe. A first sera sample from one or more hosts infected with or previously infected with the microbe is adsorbed 20 with cells or cellular extracts of the microbe that have been grown *in vitro*. Each host is in about the same stage of the infection. A second sera sample from one or more hosts infected with or previously infected with the microbe is adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Each host is in about the same stage of the infection and the stage of

the infection is different from the stage of infection in the first sample. Unadsorbed antibodies from the first serum sample and from the second serum sample are isolated. A first expression library of the microbe is probed with the unadsorbed antibodies from the first serum sample, and a second expression library is probed with the unadsorbed antibodies from the second serum sample. The first and second expression libraries can be the same expression library. Polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum sample. The polynucleotides of the microbe that are expressed *in vivo* at different stages of infection of the microbe are compared.

Still another embodiment of the invention provides a method of comparing polynucleotides of a microbe that are expressed *in vivo*, wherein the microbe has infected its host by different routes of infection. A first sera sample from one or more hosts infected with or previously infected with the microbe is adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Each host has been infected by about the same route of infection. A second sera sample from one or more hosts infected with or previously infected with the microbe are adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Each host has been infected by about the same route of infection, and the route of infection is different from the route of infection for the first sample. Unadsorbed antibodies are isolated from the first serum sample and from the second serum sample. A first expression library of the microbe is probed with the unadsorbed antibodies from the first serum sample, and a second expression library is probed with the unadsorbed antibodies from the second serum sample. The first and second expression libraries can be the same expression library. The polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum sample and the

polynucleotides of the microbe that are expressed *in vivo* by different routes of infection of the microbe are compared.

Another embodiment of the invention provides a method of confirming an animal model of microbial infection as a valid model. A first sera sample from one or more animal model hosts infected with or previously infected with a microbe, is adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. A second sera sample from one or more second hosts infected with or previously infected with the microbe, is adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*, where the second host is a different species of animal than the animal model host. Unadsorbed antibodies are isolated from the first serum sample and from the second serum sample. A first expression library of the microbe is probed with the unadsorbed antibodies from the first serum sample, and a second expression library is probed with the unadsorbed antibodies from the second serum sample. The first and second expression libraries can be the same expression libraries. Polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum sample and polynucleotides of the microbe that are expressed *in vivo* in the animal model host and the second host are compared. If the polynucleotides expressed *in vivo* in the animal model and in the second host are the same or similar, then the animal model is confirmed as a valid model.

Yet another embodiment of the invention provides a purified polypeptide comprising at least 5 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.

Even another embodiment of the invention provides a purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.

Another embodiment of the invention provides a purified polynucleotide comprising at 5 least about 15 contiguous nucleic acids of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19.

Yet another embodiment of the invention provides a purified polynucleotide comprising 10 a sequence selected from the group consisting SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19.

Another embodiment of the invention provides a method for identifying the presence of 15 a first polynucleotide. A sample suspected of containing the first polynucleotide is contacted with a second polynucleotide comprising at least about 15 nucleotides of a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19, under hybridization conditions.

The presence of a hybridized first and second polynucleotide complex is detected and the 20 presence of the first polynucleotide is identified.

Still another embodiment of the invention provides a method of eliciting an immune response. A purified polypeptide comprising at least about 5 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID

NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20 is administered to an animal. An immune response is elicited.

Even another embodiment of the invention provides a method of treating, preventing, or ameliorating a disease or infection caused by *A. actinomycetemcomitans*. A purified polypeptide 5 comprising at least about 5 contiguous amino acids of an amino acid sequence selected from the group consisting of SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20 is administered to an animal. The disease or infection is treated, prevented, or ameliorated.

The invention thus provides methods for identifying antigens expressed during an actual 10 microbial infection that do not rely on animal models. The methods can be used with microbes for which there is no well established or reliable means for genetic manipulation and allow for the analysis of a pool of strains of a microbe that represent all of the various clinically important clonotypes. The methods of the invention further provide a technique of defining a timeline for 15 antigen production by the microbe throughout the course of a natural infection process. The staging of individual *in vivo* induced antigens provides relevant information on the pathogenesis of the microorganism and on the host response to the infection. This in turn provides valuable insights for rationale vaccine design, diagnostics, and antibiotherapy.

The combination of screening, confirmation, and staging methods of the invention to identify and test *in vivo* induced antigens is far superior to existing *in vivo* expression 20 technologies by virtue of its efficiency and direct assessment in natural human infections. The methods are rapid and simple, which renders the screening of a whole genome possible in a timely fashion.

The invention further provides for the first time methods for a comprehensive analysis of the expression of infection-related antigens at the genomic level of different clinical strains of a microbe and of different stages of infection in the host.

Additionally, polynucleotides isolated by the methods of the invention can
5 advantageously be studied by conventional techniques, including mutant analysis in animal models, with the confidence that the polynucleotide is actually expressed in infections, which is not the case with other available technologies.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows an *in vivo* induced antigen technology (IVIAT) scheme. IVIAT can begin
10 with serum from one or more patients who have or recently had the disease or infection of interest. Such sera are individually tested to verify that they exhibit measurable antibody titers versus the microbial pathogen. One or more such reactive serum samples are adsorbed with cultured cells and lysates of the pathogen to remove antibodies reactive with antigens made during *in vitro* growth. The resulting adsorbed serum still contains antibodies reactive with
15 immunogenic proteins produced by the pathogen only during *in vivo* growth. It is used to probe an expression library of the pathogen's DNA or RNA cloned in a convenient host. Reactive clones are isolated, and the cloned insert is sequenced. If more than one open reading frame is present on an insert, each is individually subcloned and retested with the adsorbed serum to identify which one encodes the reactive antigen. For independent verification, the polynucleotide
20 is overexpressed, and the resulting recombinant protein is purified and used to raise monospecific antibodies. The antibodies are used to probe biological samples taken from patients infected with the pathogen. Reactivity with cells of the pathogen in clinical samples, but not with cells of the

pathogen grown *in vitro*, provides direct confirmation that the antigen is expressed only during *in vivo* growth.

Figure 2 shows sequential adsorption of pooled serum to eliminate antibodies reactive with *in vitro* expressed antigens. The pooled sera were subjected to five successive adsorptions 5 with whole cells, two adsorptions with French press extracts, and two adsorptions with heat denatured French press extracts.

Figure 3 shows the probing of a partial genomic library. Plates containing appropriate numbers of colonies were replicated onto medium with IPTG to induce expression of the cloned fragments. The colonies were lifted onto duplicate membranes, which were then reacted with 10 either the pooled unadsorbed (panel A) or pooled adsorbed (panel B) sera. Reactive clones were visualized by probing with peroxidase-conjugated goat anti-human immunoglobulin as a secondary reagent followed by development with a chemiluminescent substrate and autoradiography.

Figure 4 shows specific *in vivo* induction of Aa2008. Plaque samples were thawed on 15 ice, homogenized by brief vortexing at 4°C, and immediately heat-fixed on microscope slides. Plaque samples and matched *in vitro* grown *A. actinomycetemcomitans* isolates taken from selective medium (Slots, *Clin. Microbiol.* 15:606 (1982)) were probed in parallel with FITC-labeled monospecific antibody directed against antigen Aa2008 and the TR-labeled *A. actinomycetemcomitans*-specific monoclonal antibody. Samples were examined by fluorescence 20 microscopy (excitation wavelength 488 nm). Double color analysis, using matched differential emission filters, was performed to identify individual cells that were simultaneously labeled with FITC and TR. Bacterial cells in plaque that reacted with TR-labeled anti-*A. actinomycetemcomitans* monoclonal antibody (panel A) also reacted with FITC-labeled anti-

Aa2008 antibody (panel B) and these signals were found to colocalize (panel C). In contrast, matched *in vitro* grown *A. actinomycetemcomitans* reacted with the TR-labeled anti-*A. actinomycetemcomitans* monoclonal antibody (panel D) but not with FITC-labeled anti-Aa2008 antibody (panel E) and therefore no colocalization was observed (panel F).

5 Figure 5 shows western blot analysis of immunoreactivity of patient and control subjects' sera to Aa2008. Western blots of the inclusion body preparation of Aa2008 were probed using individual, unadsorbed sera from 20 periodontitis patients and 9 control subjects.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods and compositions for identifying and isolating 10 polynucleotides that are expressed only during *in vivo* growth of a microbe or pathogen. Briefly, the methods, termed *in vivo* induced antigen technologies (IVIAT), comprise obtaining a sample of antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro* and adsorbing these antibodies with cells or cellular extracts of the microbe that have been grown *in vitro*. An example of a sample of antibodies that can be used in the invention is sera from 15 patients who have been or are infected with the microbe. *See, e.g.* Figure 1. The unadsorbed antibodies are isolated and are used to probe an expression library of the microbe's DNA or RNA. Reactive clones can be isolated and the cloned fragments sequenced.

IVIAT Methodology

A sample of antibodies against antigens that are expressed by a microbe *in vivo* and *in* 20 *vitro* is collected. The sample can comprise the serum of a host or hosts infected with or previously infected with the microbe. Because a host from which serum is collected has undergone or is actively engaged in an actual infection by the microbe of interest, the host's serum contains antibodies produced against microbial antigens expressed during the *in vivo*

infectious process. Serum from an individual host may be used or pooled sera from two or more hosts can be used. For example, sera from about 2, 5, 25, 100, 500, or 1,000 hosts may be pooled for use in the instant invention.

The optimum number of serum samples to use depends on the type of information that
5 is being sought. If the main interest is in targets for vaccines and diagnostics, one or several sera samples should suffice to identify those proteins that are immunogenic in most individuals. On the other hand, if the main interest is a more detailed analysis of the potential molecular mechanisms used by the pathogen, the use of a larger pool of sera would reduce the possibility of missing genes or polynucleotides of interest due to variability in the human immune response.

10 In cases where the pathogen causes protracted disease, pooled serum from patients in early, middle and late stages of infection or sequential samples taken from patients during acute and convalescent phases of infection would offer the best chance of identifying transiently expressed *in vivo* induced proteins. Also, certain pathogens can infect humans by more than one route (*e.g.*, via a wound, gastrointestinal tract, respiratory tract, or skin); in such cases, selective pooling of
15 serum from patients infected by various routes may enable the identification of route-specific *in vivo* induced proteins. In cases where different clonal variants or strains of the microbe cause disease, selective pooling of serum from patients infected by various clonal variants or strains can enable the study of the pathogenesis of each variant or strain.

A host may be any kind of animal. For example, hosts can comprise humans, baboons,
20 chimpanzees, macaques, cattle, sheep, pigs, horses, goats, dogs, cats, rabbits, guinea pigs, rats, mice, chickens, ducks, fish, and shellfish.

The microbe or pathogen can be any kind of a bacterium, a virus, a parasite, a prion, or a fungus. For example, the microbe can be *Candida*, *Aspergillus*, *Sporothrix*, *Blastomyces*,

Histoplasma, Cryptococcus, Pneumocystis, Coccidioides, Tinea, Toxoplasma, Plasmodium, Pseudomonas, Actinobacillus, Staphylococcus, Bacillus, Clostridium, Listeria, Corynebacterium, Actinomyces, Mycoplasma, Nocardia, Bordetella, Brucella, Francisella, Legionella, Enterobacter, Escherichia, Klebsiella, Proteus, Salmonella, Shigella, Streptococcus, Yersinia, Vibrio, Campylobacter, Helicobacter, Bacteroides, Chlamydia, Borrelia, Treponema, Leptospira, Aeromonas, Rickettsia, Ascaris, Cryptosporidium, Cyclospora, Entamoeba, Giardia, Shistosoma, Trypanosoma, herpes virus, cytomegalovirus, Epstein-Barr virus, hepatitis virus, adenovirus, papillomavirus, polyomavirus, enterovirus, rotavirus, influenza virus, paramyxovirus, rubeola virus, rhabdovirus, human immunodeficiency virus, arenavirus, rhinovirus, and reovirus. The microbe or pathogen can also be any kind of veterinary microbe or pathogen. See e.g., Veterinary Microbiology, Hirsh & Zee, Eds., Blackwell Science, Inc., Malden, MA, 1999; Clinical Veterinary Microbiology, Quinn, Ed., Wolfe Publishing, London, (1994).

Antibodies which bind to antigens that are produced during *in vitro* propagation of the microbe of interest are eliminated from the sample of antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro*. The antibodies that are produced *in vitro* can be removed from the sample by, for example, adsorption. Preferably, a sample containing antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro*, such as a serum sample of an infected host, are contacted with *in vitro* grown whole cells, cell extracts or both of the microbe, or whole cells, extracts of whole cells, or both of cells that are infected with the microbe of interest, e.g. a prokaryotic or eukaryotic cell infected with a virus or parasite.

All or substantially all of the antibodies in the antibody sample whose corresponding antigens are derived from *in vitro* grown microbes will bind to these antigens to form immune

complexes. However, antibodies directed against antigens that are specifically expressed during the *in vivo* infectious process will remain uncomplexed since their corresponding antigens are not present in the *in vivo* grown cells and/or cell extracts. The adsorbtion step can be performed by, for example, contacting the antibody sample with whole cells and/or cell extracts that are 5 immobilized on a solid support, such as a nitrocellulose membrane. *See*, Brady & Daphtary, *J. Infect. Dis.* 158:965-972 (1988). Optionally, the whole cell and/or cell extract sample can be denatured before use to expose additional immunoreactive epitopes. Several successive adsorbtions can be performed using the same or different adsorbtion methodologies.

After the adsorbtion step or steps, unbound antibodies are separated from the antibody-10 antigen complexes. After elimination of antibodies produced in response to microbial antigens expressed *in vitro*, the sample will comprise antibodies produced in response to antigens expressed *in vivo*. This sample can then be used to screen one or more, same or different, genomic expression libraries, for example, plasmid or bacteriophage genomic expression libraries, of the microbe of interest. Methods of constructing genomic expression libraries are 15 well known in the art. *See, e.g.*, Ausubel (ed.), *Current Protocols in Molecular Biology*, John Wiley and Sons, Inc. (1994); T. Maniatis, E. F. Fritsch and J. Sambrook, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor laboratory, Cold Spring Harbor, N.Y. (1989). Optionally, DNA or RNA from more than one strain or clonal variant of the microbe of interest can be pooled for expression library construction. Methods for screening these libraries with one 20 or more labeled or unlabeled antibody-containing samples and for identifying and isolating clones from the library that encode the reactive antigens of interest are also well known in the art, *e.g.*, colony blotting methods *See, e.g.*, Ausubel (1994); Maniatis (1989).

Reactive clones identified by screening expression libraries of the microbe of interest can be characterized by conventional analysis. For example, the clone can be sequenced and the presence of open reading frames can be predicted, for example, using Fickett's, start/stop codon or other methods. See, e.g., Fickett, *Nucleic Acids Res.* 10:5303-5318 (1982); Solovyev, *Nucleic Acids Res.* 22:5156-5163 (1994); Saqi, *Protein Eng.* 8:1069-1073 (1995), Ladunga and Smith, *Protein Eng.* 20:101-110 (1997); Birney, *Nucleic Acids Res.* 24:2730-2739 (1996).

Identification of signal sequences, particularly likely ribosome binding sites and transcription termination sequences, can also be made since the information provided by these analysis can be helpful in prioritizing the subcloning of open reading frames if more than one is present on the cloned insert. Moreover, the obtained sequence information can be used to identify sequence similarities to known polynucleotides, e.g., by BLAST analysis, and possible relationships to proven or putative virulence factors can be evaluated. In instances where more than one open reading frame is present on a cloned insert, all of them may be analyzed for their ability to express *in vivo* induced antigens. For example, each open reading frame can be independently subcloned and tested with the adsorbed serum to identify *in vivo* induced antigens.

In vivo induced antigens identified by IVIAT can be directly verified as actually expressed by the microbe at the site of infection in the host by directly probing biological samples taken from disease sites of infected patients by any method known in the art. For example, a polypeptide which is expressed from a clone suspected of expressing an *in vivo* induced antigen can be used to raise polyclonal antibodies in mice. Optionally, the polynucleotide encoding the suspected antigen can be overexpressed and the resulting polypeptide purified and used to raise polyclonal antibodies. The antibodies can be labeled with, for example, fluorescein isothiocyanate (FITC). A biological sample from a disease site of a host

infected with the microbe of interest is obtained. The biological sample and a matched *in vitro* grown sample of the microbe are assayed by, for example, immunofluorescence microscopy. The labeled antibodies will react with the microbe found in the biological sample, but will not react with *in vitro* grown cells. These results can provide direct evidence that the microbe
5 expresses the IVIAT antigen exclusively during *in vivo* growth.

Once an antigen has been identified and confirmed as an *in vivo* induced antigen, the purified antigen can be used to screen the sera of individual patients for reactive antibodies. For example, a serum sample can be obtained from a patient suspected of having a particular microbial infection. The sample can be probed for reactive antibodies with a labeled, purified
10 antigen.

For those microbes that actually have a validated animal model, the polynucleotides identified by IVIAT can also be studied by conventional techniques, including mutant analysis, with the *a priori* confidence that the polynucleotide is actually expressed and relevant in host infections. IVIAT can also be used to validate *in vitro* and animal models by identifying those
15 that reproduce the same or similar expression pattern seen with IVIAT in humans or other animal hosts. These confirmed models can then be used for further conventional analysis of the pathogen.

Polypeptides

Polypeptides of the invention can either be full-length polypeptides or fragments of
20 polypeptides. For example, fragments of polypeptides of the invention can comprise about 5, 10, 25, 50, 100, 200, 250, 500, 750, or 1,000 amino acids of polypeptides of the invention. Examples of polypeptides of the invention include *Actinobacillus Actinomycetemcomitans (Aa)* SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID

NO:20. Homologous amino acid sequences which are at least about 75, preferably about 90, 96, 98, or 99% identical to the nucleotide sequences shown in SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20 are also *Aa* polypeptides.

Percent sequence identity has an art recognized meaning and there are a number of methods to measure identity between two polypeptide or polynucleotide sequences. See, e.g., Lesk, Ed., *Computational Molecular Biology*, Oxford University Press, New York, (1988); Smith, Ed., *Biocomputing: Informatics And Genome Projects*, Academic Press, New York, (1993); Griffin & Griffin, Eds., *Computer Analysis Of Sequence Data, Part I*, Humana Press, New Jersey, (1994); von Heinje, *Sequence Analysis In Molecular Biology*, Academic Press, (1987); and Gribskov & Devereux, Eds., *Sequence Analysis Primer*, M Stockton Press, New York, (1991). Methods for aligning polynucleotides or polypeptides are codified in computer programs, including the GCG program package (Devereux *et al.*, *Nuc. Acids Res.* 12:387 (1984)), BLASTP, BLASTN, FASTA (Atschul *et al.*, *J. Molec. Biol.* 215:403 (1990)), and Bestfit program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711) which uses the local homology algorithm of Smith and Waterman (*Adv. App. Math.*, 2:482-489 (1981)). For example, the computer program ALIGN which employs the FASTA algorithm can be used, with an affine gap search with a gap open penalty of -12 and a gap extension penalty of -2.

When using any of the sequence alignment programs to determine whether a particular sequence is, for instance, about 95% identical to a reference sequence, the parameters are set such that the percentage of identity is calculated over the full length of the reference polynucleotide and that gaps in identity of up to 5% of the total number of nucleotides in the reference polynucleotide are allowed.

Polypeptides of the invention further comprise biologically functional equivalents of at least about 5, 10, 25, 50, 100, 200, 250, or 500 amino acids of the polypeptides shown in SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20. A polypeptide is a biological equivalent if it reacts about the same to a polypeptide of the invention in an assay such as an immunohistochemical assay, an ELISA, an RIA, or a western blot assay. Preferably, the assay is a competition assay wherein the biologically equivalent polypeptide is capable of reducing binding of the polypeptide of the to a corresponding reactive antigen or antibody by about 80, 95, 99, or 100%.

5 Polypeptides of the invention preferably comprise an antigen that is recognized by an antibody reactive against the microbe of interest. The antigen preferably comprises one or more epitopes (or antigenic determinants). An epitope can be a linear, sequential epitope or a conformational epitope. Epitopes within a polypeptide of the invention can be identified by several methods. *See, e.g.*, U.S. Patent No. 4,554,101; Jameson & Wolf, *CABIOS* 4:181-186 (1988). For example, a polypeptide of the invention can be isolated and screened. A series of 10 short peptides, which together span the entire polypeptide sequence, can be prepared by proteolytic cleavage. By starting with, for example, 100-mer polypeptide fragments, each fragment can be tested for the presence of epitopes recognized in an enzyme-linked immunosorbent assay (ELISA). For example, in an ELISA assay a microbial polypeptide, such as a 100-mer polypeptide fragment, is attached to a solid support, such as the wells of a plastic 15 multi-well plate. A population of antibodies are labeled, added to the solid support and allowed to bind to the unlabeled antigen, under conditions where non-specific adsorption is blocked, and any unbound antibody and other proteins are washed away. Antibody binding is detected by, for 20 example, a reaction that converts a colorless substrate into a colored reaction product.

Progressively smaller and overlapping fragments can then be tested from an identified 100-mer to map the epitope of interest.

Preferably, a polypeptide of the invention is produced recombinantly. A polynucleotide encoding a polypeptide of the invention can be introduced into a recombinant expression vector, 5 which can be expressed in a suitable expression host cell system using techniques well known in the art. A variety of bacterial, yeast, plant, mammalian, and insect expression systems are available in the art and any such expression system can be used. Optionally, a polynucleotide encoding a polypeptide can be translated in a cell-free translation system.

If desired, a polypeptide can be produced as a fusion protein, which can also contain 10 other amino acid sequences, such as amino acid linkers or signal sequences, as well as ligands useful in protein purification, such as glutathione-S-transferase, histidine tag, and staphylococcal protein A. More than one polypeptide of the invention can be present in a fusion protein.

Polynucleotides

Polynucleotides of the invention contain less than an entire microbial genome and can 15 be RNA or single- or double-stranded DNA. Preferably, the polynucleotides are purified free of other components, such as proteins and lipids. The polynucleotides of the invention encode the polypeptides described above. Polynucleotides of the invention can also comprise other nucleotide sequences, such as sequences coding for linkers, signal sequences, heterologous signal sequences, TMR stop transfer sequences, transmembrane domains, or ligands useful in protein 20 purification such as glutathione-S-transferase, histidine tag, and staphylococcal protein A.

Degenerate nucleotide sequences encoding the polypeptides of the invention, as well as homologous nucleotide sequences which are at least about 75, preferably about 90, 96, 98, or 99% identical to the nucleotide sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID

NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19 and the complements thereof are also polynucleotides of the invention. Percent sequence identity can be calculated as described in the "Polypeptides" section. Complementary DNA (cDNA) molecules, species homologs, and variants of *Aa* polynucleotides which encode biologically active *Aa* polypeptides also are *Aa* polynucleotides. Preferably, a polynucleotide of the invention comprises about 5, 10, 15, 50, 100, 500, or 1,000 nucleotides of a nucleic acid sequences shown in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19.

Polynucleotides of the invention can be isolated from nucleic acid sequences present in, for example, a biological sample, such as plaque, saliva, sputum, blood, urine, feces, cerebrospinal fluid, amniotic fluid, wound exudate, or tissue, from an infected individual. Polynucleotides can also be synthesized in the laboratory, for example, using an automatic synthesizer. An amplification method such as PCR can be used to amplify polynucleotides from either genomic DNA or cDNA encoding the polypeptides.

Polynucleotides of the invention can comprise coding sequences for naturally occurring polypeptides or can encode altered sequences which do not occur in nature. If desired, polynucleotides can be cloned into an expression vector comprising, for example, promoters, enhancers, or other regulatory elements that drive expression of the polynucleotides of the invention in host cells. An expression vector can be, for example, a plasmid, such as pBR322, pUC, or ColE1, or an adenovirus vector, such as an adenovirus Type 2 vector or Type 5 vector. Optionally, other vectors can be used, including but not limited to Sindbis virus, simian virus

40, alphavirus vectors, poxvirus vectors, and cytomegalovirus and retroviral vectors, such as murine sarcoma virus, mouse mammary tumor virus, Moloney murine leukemia virus, and Rous sarcoma virus. Minichromosomes such as MC and MC1, bacteriophages, phagemids, yeast artificial chromosomes, bacterial artificial chromosomes, virus particles, virus-like particles, 5 cosmids (plasmids into which phage lambda *cos* sites have been inserted) and replicons (genetic elements that are capable of replication under their own control in a cell) can also be used.

A vector comprising a polynucleotide of the invention can be transformed into, for example, bacterial, yeast, insect, or mammalian cells so that the polypeptides of the invention can be expressed in and isolated from cell culture. Any of those techniques which are available 10 in the art can be used to introduce polynucleotides into the host cells. These include, but are not limited to, transfection with naked or encapsulated nucleic acids, cellular fusion, protoplast fusion, viral infection, and electroporation.

Polynucleotides of the invention can be used, for example, as probes or primers to detect the presence of microbial polynucleotides in a sample, such as a biological sample. The ability 15 of such probes to specifically hybridize to microbial polynucleotide sequences will enable them to be of use in detecting the presence of complementary sequences in a given sample. Polynucleotide probes of the invention can hybridize to complementary sequences in a sample such as a biological sample, including plaque, saliva, sputum, blood, urine, feces, cerebrospinal fluid, amniotic fluid, wound exudate, or tissue. Polynucleotides from the sample can be, for 20 example, subjected to gel electrophoresis or other size separation techniques or can be dot blotted without size separation. The polynucleotide probes are preferably labeled. Suitable labels, and methods for labeling probes are known in the art, and include, for example, radioactive labels incorporated by nick translation or by kinase, biotin, fluorescent probes, and chemiluminescent

probes. The polynucleotides from the sample are then treated with the probe under hybridization conditions of suitable stringencies.

Depending on the application, varying conditions of hybridization can be used to achieve varying degrees of selectivity of the probe towards the target sequence. For applications 5 requiring high selectivity, relatively stringent conditions can be used, such as low salt and/or high temperature conditions, such as provided by a salt concentration of from about 0.02 M to about 0.15 M salt at temperatures of from about 50°C to about 70°C. For applications requiring less selectivity, less stringent hybridization conditions can be used. For example, salt conditions from about 0.14 M to about 0.9M salt, at temperatures ranging form about 20°C to about 55°C. The 10 presence of a hybridized complex comprising the probe and a complementary polynucleotide from the sample indicates the presence of the microbe or polynucleotide sequence in the sample.

Methods of Eliciting an Immune Response

Polypeptides or polynucleotides of the invention can be used to elicit an immune response in a host. Elicitation of an immune response can be used, *inter alia*, to provide model 15 systems to optimize immune responses to microbes and to provide prophylactic or therapeutic treatment against microbial infection. Elicitation of an immune response can also be used to treat, prevent, or ameliorate a disease or infection caused by a microbe or pathogen. An immune response includes humoral immune responses and cell mediated immune responses, or a combination thereof. Preferably, an immune response is a humoral immune response.

20 The generation of an antibody titer by an animal against a microbe can be important in protection from infection and clearance of infection. Detection and/or quantification of antibody titers after delivery of a polypeptide or polynucleotide can be used to identify epitopes that are particularly effective at eliciting antibody titers. Epitopes responsible for a strong antibody

response to a microbe can be identified by eliciting antibodies directed against microbial polypeptides of different lengths. Antibodies elicited by a particular polypeptide epitope can then be tested using an ELISA assay to determine which polypeptides contain epitopes that are most effective at generating a strong response. Polypeptides or fusion proteins which contain 5 these epitopes or polynucleotides encoding the epitopes can then be constructed and used to elicit a strong antibody response.

A polypeptide or a polynucleotide of the invention can be administered to an animal, such as a mouse, rabbit, guinea pig, macaque, baboon, chimpanzee, human, cow, sheep, pig, horse, dog, cat, chicken, and duck, to elicit antibodies *in vivo*. Injection of a polynucleotide has 10 the practical advantages of simplicity of construction and modification. Further, injection of a polynucleotide results in the synthesis of a polypeptide in the host. Thus, the polypeptide is presented to the host immune system with native post-translational modifications, structure, and conformation. A polynucleotide is preferably delivered as “naked DNA.”

Administration of a polynucleotide or a polypeptide can be by any means known in the 15 art, including intramuscular, intradermal, intraperitoneal, or subcutaneous injection, intranasal, mucosal, topical, and oral, including injection using a biological ballistic gun (“gene gun”). Preferably, a polynucleotide or polypeptide is accompanied by a protein carrier for oral administration. A combination of administration methods may also be used to elicit an immune response.

20 Administration of polypeptides or polynucleotides can elicit an immune response in the animal that lasts for at least 1 week, 1 month, 3 months, 6 months, 1 year, or longer. Optionally, an immune response can be maintained in an animal by providing one or more booster injections

of the polypeptide or polynucleotide at 1 month, 3 months, 6 months, 1 year, or more after the primary injection.

A composition of the invention comprising a polypeptide, polynucleotide, or a combination thereof is administered in a manner compatible with the particular composition used 5 and in an amount which is effective to elicit an immune response as detected by, for example, an ELISA, as described above. A polynucleotide is preferably injected intramuscularly to a large mammal, such as a baboon, chimpanzee, or human, at a dose of 1 ng/kg, 10 ng/kg, 100 ng/kg, 1000 ng/kg, 0.001 mg/kg, 0.1 mg/kg, or 0.5 mg/kg. A polypeptide is preferably injected intramuscularly to a large mammal, such as a human, at a dose of 0.01, 0.05, 0.5, 0.75, 1.0, 1.5, 10 2.0, 2.5, 5 or 10 mg/kg. Polypeptides and/or polynucleotides can be administered either to an animal that is not infected with a microbe of interest or can be administered to a microbe-infected animal. The particular dosages polynucleotides or polypeptides in a composition will depend 15 on many factors including, but not limited to the species, age, and general condition of the mammal to which the composition is administered, and the mode of administration of the composition. An effective amount of the composition of the invention can be readily determined using only routine experimentation. *In vitro* and *in vivo* models described herein can be employed to identify appropriate doses. If desired, co-stimulatory molecules or adjuvants can also be provided before, after, or together with the compositions.

Antibodies and Their Use

20 Antibodies of the invention are antibody molecules that specifically and stably bind to a microbial polypeptide of the invention or fragment thereof. An antibody of the invention can be a polyclonal antibody, a monoclonal antibody, a single chain antibody (scFv), or a part of an antibody. Parts of antibodies include Fab and F(ab)₂ fragments. Antibodies can be made *in vivo*

in suitable laboratory animals or *in vitro* using recombinant DNA techniques. Means for preparing and characterizing antibodies are well known in the art. See, e.g., Dean, *Methods Mol. Biol.* 80:23-37 (1998); Dean, *Methods Mol. Biol.* 32:361-79 (1994); Baileg, *Methods Mol. Biol.* 32:381-88 (1994); Gullick, *Methods Mol. Biol.* 32:389-99 (1994); Drenckhahn *et al.* *Methods Cell. Biol.* 37:7-56 (1993); Morrison, *Ann. Rev. Immunol.* 10:239-65 (1992); Wright *et al.* *Crit. Rev. Immunol.* 12:125-68(1992). For example, polyclonal antibodies can be produced by administering polypeptide of the invention to an animal, such as a mouse, a rabbit, a goat, or a horse. Serum from the immunized animal is collected and the antibodies are purified from the plasma by, for example, precipitation with ammonium sulfate, followed by chromatography, preferably affinity chromatography. Techniques for producing and processing polyclonal antibodies are known in the art.

Additionally, monoclonal antibodies directed against epitopes present on a polypeptide of the invention can also be readily produced. For example, normal B cells from a mammal, such as a mouse, immunized with polypeptide of the invention can be fused with, for example, HAT-sensitive mouse myeloma cells to produce hybridomas. Hybridomas producing microbe-specific antibodies can be identified using RIA or ELISA and isolated by cloning in semi-solid agar or by limiting dilution. Clones producing microbe-specific antibodies are isolated by another round of screening. Techniques for producing and processing monoclonal antibodies are known in the art.

Antibodies, either monoclonal and polyclonal, which are directed against microbial antigens, are particularly useful for detecting the presence of microbes or microbial antigens in a sample, such as a serum sample from a microbe-infected human. An immunoassay for a microbial antigen may utilize one antibody or several antibodies. An immunoassay for a

microbial antigen may use, for example, a monoclonal antibody directed towards a microbial epitope, a combination of monoclonal antibodies directed towards epitopes of one microbial polypeptide, monoclonal antibodies directed towards epitopes of different microbial polypeptides, polyclonal antibodies directed towards the same microbial antigen, polyclonal 5 antibodies directed towards different microbial antigens, or a combination of monoclonal and polyclonal antibodies. Immunoassay protocols may be based, for example, upon competition, direct reaction, or sandwich type assays using, for example, labeled antibody. The labels may be, for example, fluorescent, chemiluminescent, or radioactive.

The polyclonal or monoclonal antibodies may further be used to isolate microbes or 10 microbial antigens by immunoaffinity columns. The antibodies can be affixed to a solid support by, for example, adsorption or by covalent linkage so that the antibodies retain their immunoselective activity. Optionally, spacer groups may be included so that the antigen binding site of the antibody remains accessible. The immobilized antibodies can then be used to bind 15 microbes or microbial antigens from a sample, such as a biological sample including saliva, plaque, sputum, blood, urine, feces, cerebrospinal fluid, amniotic fluid, wound exudate, or tissue.

The bound microbes or microbial antigens are recovered from the column matrix by, for example, a change in pH.

Antibodies of the invention can also be used in immunolocalization studies to analyze the presence and distribution of a polypeptide of the invention during various cellular events or 20 physiological conditions. Antibodies can also be used to identify molecules involved in passive immunization and to identify molecules involved in the biosynthesis of non-protein antigens. Identification of such molecules can be useful in vaccine development.

Antibodies can be detected and/or quantified using for example, direct binding assays such as radioimmunoassay (RIA) or ELISA assays. Antibodies of the invention can be also be used to treat, prevent, or ameliorate a microbial infection, to diagnose or detect the presence or absence of a microbe, and to purify an antigen or antigens that the antibody specifically binds.

5 **Compositions Comprising Polypeptides or Polynucleotides**

The invention also provides compositions comprising polypeptides or polynucleotides. Compositions of the invention preferably comprise a pharmaceutically acceptable carrier. The carrier should not itself induce the production of antibodies harmful to the host. Pharmaceutically acceptable carriers are well known to those in the art. Such carriers include, 10 but are not limited to, large, slowly metabolized, macromolecules, such as proteins, polysaccharides such as latex functionalized sepharose, agarose, cellulose, cellulose beads and the like, polylactic acids, polyglycolic acids, polymeric amino acids such as polyglutamic acid, polylysine, and the like, amino acid copolymers, peptoids, lipitoids, and inactive, avirulent virus particles or bacterial cells.

15 Pharmaceutically acceptable salts can also be used in compositions of the invention, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, propionates, malonates, or benzoates. Especially useful protein substrates are serum albumins, keyhole limpet hemocyanin, immunoglobulin molecules, thyroglobulin, ovalbumin, tetanus toxoid, and other proteins well known to those of 20 skill in the art. Compositions of the invention can also contain liquids or excipients, such as water, saline, glycerol, dextrose, malodextrin, ethanol, or the like, singly or in combination, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents. Liposomes can also be used as a carrier for a composition of the invention.

If desired, co-stimulatory molecules, which improve immunogen presentation to lymphocytes, such as B7-1 or B7-2, or cytokines such as MIP1, GM-CSF, IL-2, and IL-12, can be included in a composition of the invention. Optionally, adjuvants can also be included in a composition. Adjuvants which can be used include, but are not limited to MF59-0, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637), referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion.

The compositions of the invention can be formulated into ingestable tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, injectable formulations, mouthwashes, dentifrices, and the like. The percentage of one or more polypeptides or polynucleotides of the invention in such compositions and preparations can vary from 0.1% to 15 60% of the weight of the unit.

The following are provided for exemplification purposes only and are not intended to limit the scope of the invention described in broad terms above. All references cited in this disclosure are incorporated herein by reference.

20

EXAMPLE 1

Identification Of In Vivo Induced Microbial Polypeptides From Actinobacillus Actinomycetemcomitans (Aa)-Infected Patients: Adsorption of LJP Serum

To demonstrate the effectiveness of IVIAT, it was used to study *in vivo* gene induction of an oral pathogen, *Actinobacillus actinomycetemcomitans* (*Aa*) the putative etiologic agent of certain periodontal diseases, and, in particular, localized juvenile periodontitis (LJP) (Slots & Ting, *Periodontol.* 2000, 20:82-121 (1999)). *Aa* is well suited for this purpose since it typically evokes a strong humoral immune response in periodontitis patients (Kinane *et al.* *Periodontol.* 2000, 20:289 (2000)) and there is currently no reliable animal model with which to study this disease.

Serum samples were obtained from 20 periodontitis patients identified by family history and clinical and radiographic examinations. Microbiological and immunological analyses indicated a role for *Aa* as the etiologic agent in each of these cases. See, e.g., Ebersole *et al.* *J. Clin. Immunol.* 3:321 (1983); Tsai *et al.*, *J. Clin. Periodontol.* 8:338 (1981). These sera were tested individually by a modified ELISA procedure (Ebersole, *J. Peridont. Res.* 15:621 (1980)) using French-press disrupted cell extracts of *Aa* strain HK1651 (ATCC Accession No. 700685) to verify that they retained their reactivity to *Aa*. HK1651 is a member of the clonotype distinguished by a 530 bp deletion in the promoter region of the leukotoxin gene, and which has been characterized as being particularly virulent and contagious. Haubek *et al.* *J. Clin. Microbiol.* 34:1576 (1996). Equal amounts (0.05 ml) of each patient's serum were then pooled. Pooled sera from patients were utilized in this instance to maximize the spectrum of antibodies reactive with *Aa* epitopes, including immunodominant ones.

Antibodies in the pooled serum that were reactive with proteins made by *Aa* HK1651 during *in vitro* cultivation were eliminated by repeated adsorbtions using the methods of Brady *et al.*, *J. Infect. Dis.* 158:965-972 (1988). Adsorbtions were performed using both whole cells and cell extracts immobilized on nitrocellulose. Briefly, 500 µl of the pooled sera were subjected

to five successive adsorbtions against *in vitro* grown whole cells of *Aa* strain HK1651. The cells were grown in BHI broth at 37°C in ambient atmosphere enriched with 5% CO₂. Each adsorbtion consisted of an overnight incubation of the pooled sera with approximately 10¹¹ bacteria in 100 µl phosphate buffered saline (PBS, pH 7.2) containing 0.02% sodium azide with 5 mild agitation at 4°C. The serum was further adsorbed by incubation overnight at 4°C with a nitrocellulose membrane (10 cm diameter) saturated with HK1651 extracts prepared by French-press treatment of 10¹¹ *in vitro* grown *Aa* cells. A final adsorbtion step was carried out using the same extract which was heat denatured in a boiling water bath (10 min.) before immobilization on nitrocellulose in order to expose additional immunoreactive epitopes.

10 To evaluate the efficiency of the adsorbtion steps, French-press cell extracts of HK1651 were immobilized in microtiter wells and, following a modified ELISA procedure (Ebersole, 1980), were reacted with serial dilutions of serum samples taken at different points in the adsorbtion process. Peroxidase-conjugated goat anti-human affinity-purified immunoglobulin (ICN Cappel; Aurora OH), reactive with all classes of human immunoglobulins, was used to 15 determine the reactive antibody titers. As shown in Figure 2, the successive adsorbtions essentially removed all of the antibodies reactive with *in vitro* grown HK1651. In preliminary studies it was determined that it was unnecessary to adsorb the serum with the *Escherichia coli* host strain since it produced a relatively low background signal.

EXAMPLE 2

20 *Expression Library Construction And Screening With LJP Serum*

Genomic expression libraries of HK1651 in PET30abc were prepared in *E. coli* strain BL21(DE3) (Novagen, Madison, WI). Briefly, genomic DNA purified from *Aa* strain HK1651 was partially digested with *Sau*3A to optimize the production of 0.5 to 1.5 kb fragments which

were purified by agarose gel electrophoresis. The fragments were ligated into the multiple cloning site of pET30a inducible expression system (Novagen; Madison, WI) that had been digested with *Bam*HI, dephosphorylated with calf intestinal phosphatase (New England Biolabs, Beverly, MA), and then transformed into *Escherichia coli* strain BL21(DE3) (Novagen). Similar 5 libraries were also constructed with pET b and c.

The resulting HK1651 genomic expression library was serially diluted and plated on brain-heart infusion (BHI) medium containing kanamycin (50 µg/ml) to generate plates containing approximately 500 colonies per plate. These colonies were replicated using sterile velvet onto duplicate BHI plates containing kanamycin and IPTG (1 mM) and incubated for 5 10 hours at 37°C to induce expression of the cloned polynucleotides. To lyse the bacteria the colonies were exposed to chloroform vapors for 15 min. and overlaid with nitrocellulose membranes for 15 min. at room temperature. The membranes were carefully removed and blocked with 5% non-fat skim-milk solution in PBS at pH 7.2 containing 0.5% Tween-20 (PBS-Tween™). The colonies were first probed with a 1:10,000 dilution of adsorbed serum (based on 15 the results shown in Figure 2) overnight at 4°C and then with a 1:10,000 dilution of goat anti-human peroxidase conjugated antiserum under the same conditions. Reactive colonies were detected using the ECL kit and Hyperfilm™ ECL (Amersham Pharmacia Biotech, Piscataway N.J.). X ray film exposure times were adjusted to optimize signal to noise.

Figure 3 demonstrates the reactivity observed when replica colony blots were probed in 20 parallel with either unadsorbed or adsorbed pooled serum. Plates containing appropriate numbers of colonies were replicated onto medium with IPTG to induce expression of the cloned fragments. The colonies were lifted onto duplicate membranes, which were then reacted with either the pooled unadsorbed (panel A) or pooled adsorbed (panel B) sera. Reactive clones were

visualized by probing with peroxidase-conjugated goat anti-human immunoglobulin as a secondary reagent followed by development with a chemiluminescent substrate and autoradiography.

The majority of clones reacted with the pooled unadsorbed serum, indicating that 5 periodontitis patients had produced antibodies that recognized a broad array of *A. actinomycetemcomitans* proteins. Only a small subset of colonies tested (13 out of 20,000 screened) reacted with the pooled adsorbed serum. These IVIAT clones were isolated.








Potential bias created by using a single restriction enzyme is eliminated by using a second restriction enzyme (e.g., *Mbo*I), DNA sheared by a HydroShear™ apparatus (GeneMachines, San 10 Carlos CA), or sonically sheared DNA to create a second, independent expression library in, for example, pET30abc. In the latter case, purified HK1651 DNA at a concentration of approximately 1 µg/µl is treated on ice with 3 second resonance frequency bursts of sonication using a Microson Ultrasonic Cell Distructor (Heat Systems-Ultrasonics, Inc.). Samples taken at each time point are analyzed by agarose gel electrophoresis to determine the conditions 15 required to optimize production of 0.75 to 1.5 Kb fragments. These conditions are employed in a large scale experiment to generate sufficient starting material for library construction. Terminal overhangs are removed with Klenow and dNTPs and the resulting blunt end products are ligated into the dephosphorylated *Eco*RV restriction site in the pET30abc multiple cloning site. The vector library is then be transformed into *E. coli* host strain, BL21 (DE3), with clones selected 20 on BHI/kanamycin medium as previously described. Plates containing appropriate numbers of colonies are probed with the adsorbed serum and reactive colonies are detected using peroxidase-labeled goat anti-human immunoglobulin. Reactive colonies are isolated and their vector DNA purified.

EXAMPLE 3*Characterization Of Polynucleotide Clones Reactive With Adsorbed LJP Serum*

Sequencing of the cloned inserts in both directions indicated that the 13 recovered clones consisted of 8 unique clones. See SEQ ID NOS:1-8. MacVector v.6.0.1 was used to identify

5 open reading frames using both Fickett's and start/stop codon methods. In every instance, potential open reading frames were present on the cloned inserts oriented in both the same and opposite direction relative to the pET promoter (Table 1).

Table 1. Characterization of the IVIAT open reading frames. (* Putative ribosome binding site.)

IVIAT clone	Schematic representation of ORFs	IPTG inducibility
17		+
26		+
30		+
37		+
39.1		+
46-2		+
47-4		-
58-3		-

In order to determine which of these was most likely to be the one encoding the antigen reactive with the adsorbed serum, a colony lift method was first used to determine if the level of expression of the antigen was regulated by IPTG. Briefly, Each IVIAT clone was grown 5 overnight at 37°C in BHI broth containing kanamycin, the cells were concentrated 200-fold, and 1 µl of each culture was spotted on BHI agar plates containing kanamycin with or without IPTG. Following incubation of the plates at 37°C for five hours, the colonies were partially lysed with chloroform vapors, lifted onto nitrocellulose membranes, and reacted with the adsorbed serum. Two negative controls were included in this IPTG induction assay, namely pET30a/BL21(DE3) 10 with no cloned insert and a randomly selected clone (IVIAT-47) which contained a cloned DNA insert, but was non-reactive with the adsorbed serum.

This assay demonstrated that 6 of the 8 IVIAT clones expressed immunoreactive proteins that were induced by IPTG. *See Table 1 and SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:19.* Therefore, their open reading frames of 15 interest were likely cloned in the same orientation as the endogenous pET30 promoter. Their translation may either be initiated at the pET30 ribosome binding site or at their own ribosome binding site. We further examined 6 of the 11 possible open reading frames found in the IPTG inducible clones (Table 2). Each of these open reading frames was individually amplified by PCR and subcloned so that it was in-frame and under control of the pET30EkLIC (Novagen, 20 Madison, Wisconsin) IPTG regulated promoter. *See SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, and SEQ ID NO:20.* Reactivity with the adsorbed serum and IPTG inducibility of these subclones was confirmed using the colony lift method used previously (Table 2).

Table 2. Confirmation and characterization of the IVIAT subclones.

Subclone	Reactivity with human sera (+IPTG)	Strongest homology (identity at amino acid level)	Organism	Possible biological role	Reference
pET30b/ BL21(DE3)	●	N/A	N/A	N/A	
Aa2004	●	HpaA (67%)	H. influenzae	Virulence associated lipoprotein	(14)
Aa2005	●	Orf4 (100%)	16. actinomy-cetemcomitans	Glycosyltransferase	(15)
Aa2008	●	H10701 (68%)	H. influenzae	Unknown	
Aa2009	●	SurE (63%)	H. influenzae	Stress associated	(16)
Aa2010	●	H10457 (83%)	H. influenzae	Unknown	
Aa2011	●	KthY (69%)	H. influenzae	Thymidylate kinase	(17)

14. Chanyangam *et al.*, *Infect. Immun.* 59:600 (1991).
15. Yoshida *et al.*, *Infect. Immun.* 66:107 (1998).
16. Li *et al.*, *J. Bacteriol.* 176:6015 (1994).
17. Fleischmann *et al.*, *Science* 269:496 (1995).

Four polynucleotides with demonstrable homology were found, including one (Aa2004) that is related to a known virulence factor (*hlpA*) in the closely related organism, *Haemophilus influenza*. There are three examples of polynucleotides with homology to genes encoding proteins with known function but with previously undemonstrated relevance to pathogenesis (Aa2005; Aa2009; Aa20011). Two polynucleotides were found with no homologues identified to date (Aa2008; Aa20010). These types of *in vivo* induced polynucleotides may well represent entirely novel virulence factors of *Aa*. Interestingly, none of the open reading frames thus far identified on the clones isolated by this invention show homology to genes with known housekeeping functions. The reason for this difference is uncertain, but this represents an important additional advantage of the method described herein.

EXAMPLE 4

Verification of Specific In Vivo Expression

It is possible to directly verify that *in vivo* induced antigens identified by IVIAT are actually expressed by the pathogen when it is growing at the site of infection in the human host. To accomplish this, a method to directly probe biological specimens taken from disease sites of infected patients was developed. The first step in this process involved optimization of recombinant protein production by the subclones obtained in the previous step. Clone Aa2008 contains a 495 bp open reading frame (SEQ ID NO:13) for a hypothetical protein subcloned into pET30EkLIC (Table 2). Including the 5' and 3' sequences added by the vector, the molecular weight of the translated product should be approximately 28 Kda. Aa2008 was incubated in BHI broth containing kanamycin and IPTG (5 mM). Samples of the culture were removed at hourly intervals and analyzed by SDS-PAGE to determine the incubation time required for maximum

production of the cloned protein. A major band (not seen in pET30EkLIC/BL21(DE3) control samples) was found that had the expected molecular weight. Based on the results obtained, inclusion body preparations (Harlow & Lowes Eds., *Antibodies, a Laboratory Manual*, (CSHL Press, Plainview, NY, 1988)) were made from 10 ml batch cultures of Aa2008 incubated for 3 hours with IPTG. SDS-PAGE and Western blot analysis was performed to confirm that the overexpressed protein was reactive with the adsorbed serum used in the original screening. The reactive band was excised from the Coomassie stained gel and used to raise polyclonal antibodies in mice.

Three female Balb/C mice are used per antigen. The 6-8 week old mice were injected subcutaneously (sc) with the purified polypeptide, using a concentration of 20, 50, or 100 g/mouse. RIBI MPL + TDM emulsion was used as an adjuvant. Two weeks later, the immunization protocol was repeated. Approximately 10 days after the second immunization, a small amount of blood was taken from the tail vein of each mouse, and assayed by ELISA to evaluate the response to the immunogen. Where the mice were responding well (*i.e.*, detection at serum dilution greater than 1:500), one more sc injection was given 3-4 weeks after the second immunization, and four days before the scheduled hybridoma fusion. A mouse myloma cell line (Sp2/0) was cultured for several days prior to the scheduled fusion. Log phase cells were counted and washed.

The mouse exhibiting the best serum titer was anesthetized and bled out. The spleen was removed. The blood was clotted and spun down and the serum saved to be used as a positive control in the subsequent assays. The spleen cells were flushed out of the spleen capsule and separated into single cells, washed, and counted. Spleen cells were combined with Sp2/0 cells at a 7:1 ratio. Cells were pelleted by centrifugation. PEG 1500 at a concentration of 50% was

slowly added to the cell pellet and then diluted. Cells were spun down and the pellet resuspended in HAT selective medium containing 20% horse serum and 25% conditioned media. Cells were plated into 96 well plates at a concentration of 2.5×10^5 cells/well. Cells were grown in a 37°C incubator with 7% atmospheric CO₂. After several days, colonies of hybridoma cells were visible.

5 Feeding (removing and replacing approximately 50% of the total volume of growth medium) was performed at day seven and again at day nine or ten. When the hybridoma cells were nearly confluent in each well, a portion of the supernatant was removed and assayed by ELSIA to detect the presence of the desired antibody. The cells in the wells that tested positive on the primary screen were transferred to a 24 well plate, and the supernatant tested again by ELISA. The

10 antibody activity and preliminary heavy chain isotype of each mass culture was determined and the wells that scored positive during this secondary round of screening were transferred to 6 well plates. At this point the cells were designated as mass cultures. Each mass culture chosen was cultured briefly in 6 well plate wells in order to freeze two vials of cells. Supernatant was saved for future expanded screening. The best mass cultures were selected for ascites production.

15 Ascites were induced by intraperitoneal injection into one female Balb/C mouse, which was monitored daily for 7 days. The ascitic fluids were collected every day for 3 days (for a final volume of ca. 10ml).

Ascites fluid were filtered and circulated over a protein A affinity column to affinity purify IgG. The polyclonal antibodies were washed and eluted with 0.1 M glycine, pH 3.0,

20 followed by neutralization with Tris, pH 9-10. The recovered antibodies were concentrated, and the buffer exchanged to 1 x PBS with 0.02% azide. The yield and quality of the antibodies were evaluated spectrophotometrically (280 nm) and by SDS-PAGE, respectively.

The purified IgG was shown to react in western blots with a protein of the appropriate size in extracts and inclusion body preparations made from clone Aa2008. The antibodies were labeled directly with fluorescein isothiocyanate (FITC) (Molecular Probes, Eugene, OR, USA).

A murine monoclonal antibody specific for *Aa*, Mab 13(10B2), was labeled with Texas-red (TR).

Subgingival plaque from patients with LJP was sampled at the time of their diagnosis. Sterile paper points were inserted into mesial, buccal and distal sites of all four first molars that had significant (greater than or equal to 5 mm) bone loss. The points were immediately immersed in ice-cold BHI broth containing 50% glycerol, and after removing a small sample for 10 microbiological identification of *Aa*, they were quick frozen in a dry ice/ethanol bath and stored at -80C. Samples which were confirmed to contain *Aa* by growth on selective medium were used to directly demonstrate the presence of Aa2008.

Plaque samples and matched *in vitro* grown cells were assayed by immunofluorescence microscopy (Fig. 4). Briefly, plaque samples were thawed on ice, homogenized by brief 15 vortexing at 4°C, and immediately heat-fixed on microscope slides. Plaque samples and matched *in vitro* grown *Aa* isolates taken from the selective medium were probed in parallel with FITC-labeled monospecific antibody directed against antigen Aa2008 and the TR-labeled *Aa*-specific monoclonal antibody. Samples were examined by fluorescence microscopy (excitation wavelength 488 nm). Double color analysis, using matched differential emission filters, was 20 performed to identify individual cells that were simultaneously labeled with FITC and TR. Bacterial cells in plaque that reacted with TR-labeled anti-*Aa* monoclonal antibody (Figure 4A) also reacted with FITC-labeled anti-Aa2008 antibody (Figure 4B) and these signals were found to colocalize (Figure 4C). In contrast, matched *in vitro* grown *Aa* reacted with the TR-labeled

anti-*Aa* monoclonal antibody (Figure 4D), but not with FITC-labeled anti-*Aa*2008 antibody (Figure 4E) and therefore no colocalization was observed (Figure 4F). These results provide direct evidence that *Aa* expresses antigen Aa2008 exclusively during *in vivo* growth.

Each anti-IVIAT antibody may independently screen against all of the plaque samples 5 collected (3 samples/tooth x maximum 4 teeth/patient x 10 patients = 120 samples) in order to optimize the identification of *Aa* growing under environmental conditions appropriate for expression of the *in vivo* induced antigen. *Aa*-deficient samples are included to serve as an additional negative control for the species specific antibody and to identify possible cross-reacting antigens presented by other species that may be present in plaque. Based on our 10 previous studies, we expect that approximately 75% of samples will contain measurable numbers of *Aa*. Of the three most likely outcomes, there will be instances where cells react with Texas red-labeled anti-*Aa* antibody and one or all of these cells also react with a FITC-labeled anti-IVIAT antibody. This indicates that particular antigen is produced by *Aa* during growth in a site of infection. There is no requirement for all of the *Aa* cells in a sample to react with the anti- 15 IVIAT antibody since there are likely to be numerous microenvironments present at each sampling site. As a second possible outcome, there may be instances where none of the cells which react with the Texas red-labeled anti-*Aa* antibody also react with a particular FITC-labeled anti-IVIAT antibody. This indicates that none of the plaque samples were taken from sites presenting the necessary environmental stimulus. Clearly, by using a large number of plaque 20 samples taken from patients in different stages of infection, we hope to reduce the occurrence of this possibility. This result may also indicate that the *in vivo* induced antigen was expressed but not surface localized. Thus, in situations where a particular anti-IVIAT antibody does not react with *Aa* cells in any of the plaque samples, one may examine intra- and extra-cellular

compartments for the antigen. This is done simply by examining plaque sample homogenates using a capture ELISA method: microtiter wells are coated with unlabeled anti-IVIAT antibody, reacted with homogenate, and then probed with FITC-labeled anti-IVIAT antibody according to Current Protocols in Immunology, John Wiley & Sons, NY (1998). The presence of reactivity, 5 as measured by fluorescent light emission, is then correlated to the presence of *Aa* as determined by prior microbiological, ribotyping and immunological analyses of the plaque samples. As another possible outcome of interest, plaque samples may contain cells that react with a particular FITC-labeled anti-IVIAT antibody but which do not react with Texas red-labeled anti-*Aa* antibody. These are likely to represent instances where plaque samples contain other bacterial 10 species which produce a cross-reacting antigen. However, it is also possible that these cells belong to a strain or variant of *Aa* which does not react with the species anti-*Aa* antibody. In these instances, previous culturing data along with ribotyping verification will help us to distinguish between these possibilities.

As an alternative approach to the microscopy methods described above, one may use 15 FITC-labeled anti-IVIAT antibodies and a fluorescence-activated cell sorting system (e.g., FACSsort, Becton Dickinson; Franklin Lanes, NJ). Recent reports have demonstrated the technical feasibility of using automated cell sorters for separating bacteria (Valdivia & Falkow, *Science*, 277:2007 (1997); Handfield & Levesque, *FEMS Microbiol. Rev.* 23:69-91 (1999)). In addition, FACS can be used to effectively separate *Aa* from a mixed bacterial population using 20 the green fluorescence protein (GFP) as a gene marker. In this study, a strain of *Aa* (SUNY 465) expressing the GFP under the leukotoxin ltx promoter was separated from Aa strain Y4 with the FACSsort.

EXAMPLE 5*Screening Patients for Reactive Antibodies*

Once IVIAT has identified and confirmed an *in vivo* induced antigen, the purified antigen can be used to screen the sera of individual patients for reactive antibodies. Western blots of the inclusion body preparation of Aa2008 were probed using individual, unadsorbed sera from 20 periodontitis patients and 9 control subjects (Figure 5). Densitometric analysis of Western blots showed that the patient group demonstrated significantly ($p<0.05$, independent student's T-test) higher reactivity with the recombinant Aa2008 protein (3.75 ± 1.12 , mean \pm standard deviation) than a control group that did not have periodontitis (2.79 ± 0.98). These data suggest that Aa2008 is immunogenic in periodontitis patients, and confirms the conclusion drawn from fluorescence microscopy of plaque samples that this represents an *in vivo* expressed polynucleotide.

We claim:

1. A method of identifying a polynucleotide of a microbe that is expressed *in vivo* comprising the steps of:
 - (a) adsorbing antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro* with cells or cellular extracts of the microbe that have been grown *in vitro*;
 - (b) isolating unadsorbed antibodies; and
 - (c) probing an expression library of the microbe's DNA or RNA with the antibodies of step (b);
- 10 wherein a polynucleotide of the microbe that is expressed *in vivo* is isolated and identified.
2. The method of claim 1 wherein the polynucleotide encodes an antigen.
3. The method of claim 2 wherein the antigen is capable of eliciting an immune response in an animal.
- 15 4. The method of claim 3 wherein the animal is selected from the group consisting of humans, baboons, chimpanzees, macaques, cattle, sheep, pigs, horses, goats, dogs, cats, rabbits, guinea pigs, rats, mice, chickens, ducks, fish, and shellfish.
5. The method of claim 1 further comprising the step of determining the nucleic acid sequence of the polynucleotide.
- 20 6. A method of confirming the identified polynucleotide of claim 1 as expressed *in vivo* comprising the steps of:
 - (a) expressing and isolating a polypeptide from the identified polynucleotide of claim 1;

(b) producing antibodies to the polypeptide; and
(c) probing biological samples from a host infected with or previously infected with the microbe, with the antibodies of step (b), whereby the identified polynucleotide is confirmed as being expressed *in vivo*.

5 7. The method of claim 1 wherein the antibodies of step (a) comprise sera from one or more hosts infected with, or previously infected with the microbe.

8. The method of claim 1 wherein the microbe is selected from the group consisting of a bacterium, a virus, a parasite, a prion, and a fungus.

9. The method of claim 1 wherein the microbe is selected from the group consisting 10 of *Candida*, *Aspergillus*, *Sporothrix*, *Blastomyces*, *Histoplasma*, *Cryptococcus*, *Pneumocystis*, *Coccidioides*, *Tinea*, *Toxoplasma*, *Plasmodium*, *Pseudomonas*, *Actinobacillus*, *Staphylococcus*, *Bacillus*, *Clostridium*, *Listeria*, *Corynebacterium*, *Actinomyces*, *Mycoplasma*, *Nocardia*, *Bordetella*, *Brucella*, *Francisella*, *Legionella*, *Enterobacter*, *Escherichia*, *Klebsiella*, *Proteus*, *Salmonella*, *Shigella*, *Streptococcus*, 15 *Yersinia*, *Vibrio*, *Campylobacter*, *Helicobacter*, *Bacteroides*, *Chlamydia*, *Borrelia*, *Treponema*, *Leptospira*, *Aeromonas*, *Rickettsia*, *Ascaris*, *Cryptosporidium*, *Cyclospora*, *Entamoeba*, *Giardia*, *Shistosoma*, *Trypanosoma*, herpes virus, cytomegalovirus, Epstein-Barr virus, hepatitis virus, adenovirus, papillomavirus, polyomavirus, enterovirus, rotavirus, influenza virus, paramyxovirus, rubeola virus, 20 rhabdovirus, human immunodeficiency virus, arenavirus, rhinovirus, and reovirus.

10. The method of claim 1 wherein the host is an animal selected from the group consisting of comprise humans, baboons, chimpanzees, macaques, cattle, sheep, pigs,

horses, goats, dogs, cats, rabbits, guinea pigs, rats, mice, chickens, ducks, fish, and shellfish.

11. A method of comparing polynucleotides of a microbe that are expressed *in vivo* at different stages of infection of the microbe comprising the steps of:

5 (a) adsorbing a first sera sample from one or more hosts infected with or previously infected with the microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*, wherein each host is in about the same stage of the infection;

10 (b) adsorbing a second sera sample from one or more hosts infected with or previously infected with the microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*, wherein each host is in about the same stage of the infection, wherein the stage of the infection is different from the stage of infection in step (a);

15 (c) isolating unadsorbed antibodies from the first serum sample and from the second serum sample;

(d) probing a first expression library of the microbe with the unadsorbed antibodies from the first serum sample, and probing a second expression library with the unadsorbed antibodies from the second serum sample, wherein polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum sample; and

20 (e) comparing the polynucleotides of the microbe that are expressed *in vivo* at different stages of infection of the microbe.

12. The method of claim 11 wherein the first expression library and the second expression library are the same expression library.

13. A method of comparing polynucleotides of a microbe that are expressed *in vivo*, wherein the microbe has infected its host by different routes of infection comprising the steps of:

(a) adsorbing a first sera sample from one or more hosts infected with or previously infected with the microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*, wherein each host has been infected by about the same route of infection;

(b) adsorbing a second sera sample from one or more hosts infected with or previously infected with the microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*, wherein each host has been infected by about the same route of infection, wherein the route of infection is different from the route of infection in step (a);

(c) isolating unadsorbed antibodies from the first serum sample and from the second serum sample;

(d) probing a first expression library of the microbe with the unadsorbed antibodies from the first serum sample, and probing a second expression library with the unadsorbed antibodies from the second serum sample, wherein polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum sample; and

(e) comparing the polynucleotides of the microbe that are expressed *in vivo* by different routes of infection of the microbe.

14. The method of claim 13 wherein the first expression library and the second expression library are the same expression library.

15. A method of confirming an animal model of microbial infection as a valid model

comprising the steps of:

(a) adsorbing a first sera sample from one or more animal model hosts infected with or previously infected with a microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*;

5 (b) adsorbing a second sera sample from one or more second hosts infected with or previously infected with the microbe, with cells or cellular extracts of the microbe that have been grown *in vitro*; wherein the second host is a different species of animal than the animal model host;

10 (c) isolating unadsorbed antibodies from the first serum sample and from the second serum sample;

(d) probing a first expression library of the microbe with the unadsorbed antibodies from the first serum sample, and probing a second expression library with the unadsorbed antibodies from the second serum sample, wherein polynucleotides of the microbe that are expressed *in vivo* are identified for the first and second serum 15 samples; and

(e) comparing the polynucleotides of the microbe that are expressed *in vivo* in the animal model host and the second host;

wherein if the polynucleotides expressed *in vivo* in the animal model and in the 20 second host are the same or similar, then the animal model is confirmed as a valid model.

16. The method of claim 15 wherein the first expression library and the second expression library are the same expression library.

17. The method of claim 15 wherein the animal model host and the second host are selected from the group consisting of comprise humans, baboons, chimpanzees, macaques, cattle, sheep, pigs, horses, goats, dogs, cats, rabbits, guinea pigs, rats, mice, chickens, ducks, fish, and shellfish.

5




FIG. 1

2 / 6




FIG. 2

BEST AVAILABLE COPY




FIG. 3A





FIG. 3B

4 / 6



BEST AVAILABLE COPY

FIG. 4

5 / 6

**Periodontitis
patients**
 3.75 ± 1.12 (mean \pm std dev.)**Controls** $p < 0.05$ 2.79 ± 0.98 **FIG. 5****BEST AVAILABLE COPY**

Table 2. Confirmation and characterization of the IVIAT subclones.

Subclone	Reactivity with human sera +IPTG	Strongest homology (identity at amino acid level)	Organism	Possible biological role	Reference
PET30b/ BL21(DE3)	[+IPTG]	N/A	N/A		
Aa2004	[+IPTG]	HlpA (67%)	<i>H. influenzae</i>	Virulence associated lipoprotein	(14)
Aa2005	[+IPTG]	Orf4 (100%)	16. actinomy-cetemcomitans	Glycosyltransferase	(15)
Aa2008	[+IPTG]	HI0701 (68%)	<i>H. influenzae</i>	Unknown	
Aa2009	[+IPTG]	SurE (63%)	<i>H. influenzae</i>	Stress associated	(16)
Aa2010	[+IPTG]	HI0457 (83%)	<i>H. influenzae</i>	Unknown	
Aa2011	[+IPTG]	KthY (69%)	<i>H. influenzae</i>	Thymidylate kinase	(17)

FIG. 6

BEST AVAILABLE COPY

SEQUENCE LISTING

<110> Handfield, Martin
Brady, Jeannine
Progulske-Fox, Ann
Hillman, Jeffrey D.

<120> Microbial Polynucleotides Expressed During Infection of
a Host

<130> MBHB00-505

<140>

<141>

<150> 60/147,551
<151> 1999-08-06

<160> 20

<170> PatentIn Ver. 2.1

<210> 1
<211> 849
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (566)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (625)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (627)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (636)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (650)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (656)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (661)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (672)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (681)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (720)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (723)
<223> N stands for any nucleotide.

<400> 1
gatcgcgtaa acgggttaac acggaaagca attgtttaat gtcggcaaaa tgcagccctg 60
tggtcggttc gtccagaata tacagggttt tgcccgatc ccgttggag agttccgtcg 120
ccagttcac ccgttgcgt tccccggcgg acagggtggt agaggattgc cccaagcgaa 180
tataagacaa gcccacgtca atcagggttt gcaatttacg cgcaatcatt ggaatggcat 240
cgaaaaactc ggcgcacatc tccaccgtca tgcgcgttgc acgttgcgtt ttatgttgc 300
tgttagcgat ttccagggtt tcgcgttgc aacgcttgcc ttatgttgc tgcgttgcgtt 360
cgtacacatc gggcaggaag tgcatttcca ctttgcgttgc ggcgttgcgtt tggcaggcgtt 420
acagcgcccc cgcgcacgt taaaactgaa acgccccggg ttataaccgc ggcgcacgggc 480
tttcggtacg cggccaaaca attcgcgaat cggcgtgaat acgcccgtgt aagttgcggc 540
gttggagcgt ggcgttgcgtt caatcnggtt ttggtaata tcaataacttt atcgaaaaat 600
tccaaacatt taatggactt gtacngngaa acctcngcat ttctgcacn attaangcgt 660
nttgcataat anggaacaaa ntgtcgtaa tcaatgttgcgatc ttttgcgttgcgtt 720
ccngtgatgc aggtaaataa gcccacggga atgtctaaat tgacgtttt caggttgcgtt 780
ccggaaagcgc cgaacaattt gagcattttt ttcttatcaa gtgcgttgcgtt 840
atttcgatc 849

<210> 2
<211> 357
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<400> 2
gatcactaag ttgttcaatc ctttcgttgc ggaatcttg tctaaatacg gtttatgttg 60
cattgcgtta acgtctaaat cacctttaga cactgcgttgc tttggcaagg cgtatgtatc 120
aataaaaacgt attctacgtc taagttgtat ttttgcgttgc ccacttgcgttgc tgcgttgcgtt 180
gccacttggt gttccggcgttgc tgccatcgttgc cccacttgcgttgc ttgttgcgttgc ggcttctgttca 240
gccgggtttgttgc ctttgcgttgc ggcttccgggttgc ttttgcgttgc ctttgcgttgc ttttgcgttgc 300
gaatacggag gctaatgttg ctttgcgttgc ctttgcgttgc ttttgcgttgc ttttgcgttgc 357

<210> 3
<211> 886
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (554)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (596)

<223> N stands for any nucleotide.

<400> 3

gatcaaactg gtggcgcaag ggcagcgcgt agcaaattt cccgatattt tggtctatgc 60
gcgcgtcgac aacggcatgg tagggcgacg ccgtggttt aaccaagcca aagcgaaatg 120
gcgcttattt aagctaaaac accatcttgg cattcaggga ttttatccg ggctattcac 180
ttttgtccctg cggtccggtg ccagattatt gccgacatca ttactgaaaa acatctatca 240
aacctttta agaaaaataac atgatgaaat taaactgtat tttaaaaata tccgaaattt 300
ccaccgcact ttttcttagcg ggttggccct caaattcaag tgccgcgacg caatcctctg 360
agcaggcgaa ttctgttacg gctgtgaatc ccactgcgggt gtacagtaag ccccgcaactt 420
tggataactt caacgattat gtgaatttct taaaaggtaa agcagcggca gaaggcggtt 480
ctgccgacgt attgaatgca caaaaataata ttaattatat tcaaaaatcc gtggatttgg 540
acgatcaaca agcnngcaga attcgcaagc gtgatccaaa tgccccggc atcatnaatt 600
ccgaacggca cgaccaatta cttaaatcgt gtattaacca agaataaaagt agacacggca 660
gaagcacgtt attggaaaca attgccgcag cttgaaaatg cttcaaaagaa attcagcgta 720
ccgaaaaatt atctgttagc cttgtggggc atggagagta gctttggcta ttatcaggc 780
aattacgatg ttttatccac cttagccact cttgctttt acggacgccc tgaagccta 840
ttcagcaaag aattcatcgc cgccatgaaa atgctacagc gcgatc 886

<210> 4

<211> 507

<212> DNA

<213> *Actinobacillus actinomycetemcomitans*

<220>

<221> misc_feature

<222> (4)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (9)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (21)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (23)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (29)

<223> N stands for any nucleotide.

<220>

<221> misc_feature

<222> (32)

<223> N stands for any nucleotide.

<220>

```
<221> misc_feature
<222> (35)..(36)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (39)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (42)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (45)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (49)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (52)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (58)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (61)..(62)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (65)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (69)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (73)
<223> N stands for any polynucleotide.

<220>
<221> misc_feature
<222> (97)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
```

<222> (102)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (138)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (457)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (459)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (467)
<223> N stands for any nucleotide.

<400> 4
ttgntaccnt agccgctgac nanaactanc angcnntgna tnatntcgna tnattaanat 60
nngcnagng cancagctta cctttgccga cggttcnctg tntgaaagcg ccattcgcaa 120
agtgcgggt gaggcggnga aaattcactc acttggtgcg gaaggcaatg atgtgggatt 180
gaaagcccat catggcgggt ggataaaagcg ttatTTTta tgtcggcaga tgcctttcct 240
gcgttaaatg cgTTattaga cgaAAAATTT tcgtatcagg acacagcagt ttacggcgag 300
aattttgtgg ttccgcgct gaatgaagat tccgtgtgtg tgggcgatat ttatcaaatc 360
ggctcctgca tggtggaggt gtcgcagccg cgtaaacctt gtgagcgctt atcgaaaaat 420
accaataatc cgaacacgca acaaaccgtg tacgctncng ctggtcnggc tggtatgtgc 480
cggtggtacc ccaaggggga aattcaa 507

<210> 5
<211> 1087
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (622)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (642)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (661)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (669)
<223> N stands for any nucleotide.

<220>

<221> misc_feature
<222> (685)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (690)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (700)
<223> N stands for any nucleotide.

<400> 5
gatcgcaaca agcgcagttt ctatatttcc gcccggca gtgagattt caatccaatc 60
gttgccaaac gtatggact cagtctggcg cagcaggct taaatggaga cgttttgcaa 120
ctgaacgggtt cgcacagttt gtttggcg gacgcattcg aagatttgac gcaactgcaa 180
caacgcttgg cacaacggga tattttgctt accgcaccgc ttatcggcga agaggacaaa 240
atgtcggtgg attttgagaa tgaaattttt gtgcgcgacc aagccttgg ccatttgatg 300
cggtcaagaac gcgtgaaagc cggccgcgtt ccgattttaa tgcaggcgca acagtttcaa 360
tggcaatttg aaccgaacgg tttgcgcctt aaattttatt tgccggcagg cagttacgcc 420
acggcggtgg tacgcgagct ggtgaatgtt gaaaactgaa aaacgagaag aaaaacagga 480
ataacaagaa catgaatatt ttattaagta acgtacggg cattcacgcg cccggcattc 540
gtgtgatggc agaacattgc gtaagatgtc caatgtgacc atcgtcgcgc cggacagcaa 600
ccgcaagcgc cgccttcagt tncttaacact tggtaagcc gntgtattcc gttcatggg 660
naaagcggng attattgcgt caacngcacn cccggcggan tgcgtgcata ttgcccctgac 720
gggttttctt tccggcgca tcgattttgtt gatttccggc atcaacgcgg gggcgaacct 780
ggcgcgtatatt ccggcacggc cgccgcggca tttgaagggc gtcatctggg 840
cttgcgtctt attgcgttat cgctcgatgg tcgtcaacat tttgaaacgg cggcgcgcgt 900
ggtatgcgtat ttgggtccga aattacacgc ccaatttata ggcaaacacg aaattctgaa 960
tattaacgtg cccgatgtgc cttacgaaga actgaaaggc attaaagtgt gccatggg 1020
ctaccgttctt tccgcttctg aagtgattaa acagcaaagc ccgcgtggcg aagacatgta 1080
ttggatc 1087

<210> 6
<211> 681
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (609)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (614)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (651)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (665)
<223> N stands for any nucleotide.

<400> 6
gatctgccgt tggcgaaccc ttacgaaatg ctgatcctcg cgtccatcgt ggaaaaagaa 60
accggcattg ctgcagaacg cccacaagtgc gcttcgttat tcattaatcg gtaaaaagcc 120
aaaatgaagc tgcaaaccca tccgaccgtc atttacggca tgggcgacga ctacaacggc 180
aatattcgca aaaaagattt gaaacgcac acgcctata acacctatgt gattgacggc 240
ttgccgcccga caccgattgc gatgccgagt gaagaggcgt tacaggcgtt ggcacatccg 300
gccaacgg cggttattt ttcgtggca gacggcacgg ggggacacaa attcagtgcgt 360
aatttaacg aacataacaa agcggtgca gcatatttgc gctggtaccg cgaacaaaac 420
ggaaaataat atggtaggca aatttattgt cattgaaggc ttggaaaggcg caggcaaaag 480
caccgctcat caatgcgtt gggatacgtt aaaaacgtt ggtgttggg aagtcatctc 540
tacccgcgag ccggccggca caccgttgg cgaaaaagct acgcctatctc attaaacatg 600
aaaaccaana gccngtgacc cgataaagcg gaattactca tgctgtatgc ngccgcctgc 660
aatnntggg aaaaatgtgat c 681

<210> 7
<211> 822
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (532)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (630)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (696)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (710)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (722)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (725)
<223> N stands for any nucleotide.

<400> 7
gatcgataaaa aatcagcaag gcaaccactc ttaacaagaa ttgcataacc gtccaatatc 60
gtcgccataa ctgaatcgcg tagagcatgg ctaacgcaat catagcgcgt aaagtcggaa 120
tagcaagccc cgccagttgg ctgtataaca acgaaaaat gaatccgcac agaatcggaa 180
atgtcgggct gatgtAACGC gtcggcaagg caaattgcag tagacgcgc aaggtaaaac 240
ccagcatcat cgccagtcgg atatgcagcc ctgaaaatggc aattaaatgc ggcgtatgg 300
tttttgata aatttgccaa gtttttgggt ctaagcggaa acgttcgc aaaaaccgatg 360
ccagcaacaa gccttgtcgg ggtaaaattct ccgtttgttga taaggcgttga ttgagagcgg 420
tttggcgtaa cgaaaaaaacg ttttccatt tgaccgcact tttaatctct gcccacgcgg 480
tgatgtgtt gccgaaatac catggctggc ggtcaaaaacc gtcaaaaattc angcggaaag 540
aaagcgctcg caagcgtaaa ttgcctgcgt aacgttcgc accccgttgc tgggttgctt 600

agtttccatt gcgcgtaaat acgttgtn gggaaagattt tcggcgaagt tttggcgccg 660
 aataaccagg gggttggata atgctgctga tgccanaaaat ttcccttgacn ggttaaatttc 720
 cngnggaac gggtttcgg cggcagattt gcaagattat ccgcctgggt cagtatggaa 780
 attgccgatt ggtggacgta agcggactga atcatcaaga tc 822

<210> 8
 <211> 949
 <212> DNA
 <213> *Actinobacillus actinomycetemcomitans*

 <220>
 <221> misc_feature
 <222> (538)
 <223> N stands for any nucleotide.

<400> 8
 gatcagggtt ccgttaaccgc gtaaggcggtt acccgcttaa accactcgac ctgcggcgcc 60
 ggcattgact gcttgtctgc gagaaccact gatgtcgatg cctttgttac cgccgtcgcc 120
 gtttagagaaa ccttgaatca cattgccgtt ggtcggccag cgccatgcca cgttggatac 180
 tgccgggtcg gtgcccgtt gggttatcgg ctgtatgggtt gccgggtgcag cagtacctac 240
 gccggcttta atcgggcccgg taatcgtgcc gtcggaaacca tattgtgtgc cggttgcgc 300
 cgggggttaa gttacggtcg gttcaccacc ttgcgttagcc ggttgggtga cctgtcggtt 360
 catttgcgtt gcagcttgcg tttgcacccgt aaccgttgcg cccggctca cctttaagg 420
 ttgtccgacg cttaagctgt aagggtcggaa catattttt aacgcccgcattttcac 480
 atccaaacca gaaatgttagg cgataaggaa catgggtgtca cctttgcgtt cggtatangt 540
 ttcacccccc tagaaaccc ttgtgattt gctgtatcc ggtgcgttag tggtcgggtt 600
 acctggaatg gtgaaatctt gggatgcctg ttgcgggtga attttccccg gcaggttggg 660
 tttgcctaac cccgttgtgc ttgcataatgc aaactgttgc tacatcggtt gaaaaatcgg 720
 ctgcggagta gattgtgcgc cggtegcctg tagattgttc gactggcaa tggaccgtt 780
 catcgaagcg ggtacattgc ttgttggat ttgcgggttcc catgtgtat tggccgcattc 840
 gggtgaaccg tccaccgggtt gcatgagttcc cggggataag gtaccgtcgg cggtttccac 900
 cggtgcgggt gtattcgaag tacaggccgc taacacggca atgctgatc 949

<210> 9
 <211> 277
 <212> DNA
 <213> *Actinobacillus actinomycetemcomitans*

<400> 9
 agagaaaaaaaa ccggaagccg caccggcaga caaaccggcg gcagaagccc cggcaacaat 60
 caaagtgggc gtgatggcgag gaccggaaaca ccaagtggct gaaatcgccag cgaaagtggc 120
 aaaagaaaaaaaa tacaacttag acgtagaata cgttttattt atgactacgc cttgcac 180
 actgcagtgt ctaaagggtga tttagacgtt aacgcaatgc aacataaacc gtatttagac 240
 aaagattcccc aagcgaagg attgaacaac tttagtga 277

<210> 10
 <211> 259
 <212> DNA
 <213> *Actinobacillus actinomycetemcomitans*

<400> 10
 gatcaaactg gtggcgcaag ggcagcgcgt agcaaatttta cccgatattt tggtctatgc 60
 ggcgtcgcc aacggcatgg tagggcgacg ccgtgggtt aaccaagcca aagcggaaatg 120
 gcgcttattt aagctaaaac accatcttgg cattcaggaa tttttatccg ggctattcac 180
 ttttgcctg cggtccgggtt ccagattt gccgacatca ttactgaaaa acatctatca 240
 aacctttta agaaaataa 259

<210> 11
<211> 459
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<400> 11
gatcgcaaca agcgtagttt ctatatttcc gcccggca gtgagattt caatttaatc 60
gttgccaaac gtattgaact cagtctggcg cagcaggct taaatggaga cgaaaaa 120
ctgaacgggtt cgacagttt gtttgtggcg gacgcattcg aagatttgcac gcaactgcaa 180
caacgcttgg cacaacggga tattttgtt accgcaccgc ttatggcgaa agaggacaaa 240
agtgcgggtt attttggaa tgaaattttt gtgcgcacc aaggcttgc 300
cgccaagaac gcgtgaaagc cgccccgcgt ccgattttaa tgcaggcgca acagtttcaa 360
tgccaatttgc aaccgaacgg tttgcgcctt aaattttatt tgccggcagg cagttacgcc 420
acggcggttgg tacgcgagct ggtgaatgtt gaaaactga 459

<210> 12
<211> 596
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> misc_feature
<222> (131)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (151)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (170)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (178)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (194)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (199)
<223> N stands for any nucleotide.

<220>
<221> misc_feature
<222> (209)
<223> N stands for any nucleotide.

<400> 12
atgaatattt tattaagtaa cgatgacggc attcacgcgc cgggcattcg tgtgtatggca 60
gaacattgcg taagattgcc aatgtgacca tcgtcgccggc ggacagcaac cgcaagcgcc 120
gccttcgtt ncttaacctt ggtgaagccg ntgtattccg ttcatttggaaagcggn 180
ttattgcgtc aacngcacnc ccggcgant gcgtgcataat tgccctgacg ggtttcttt 240

ccgggcgcat cgatttggtg atttccggca tcaacgcccgg ggcgaacctg ggcgatgatg 300
 tgcataattc cggcacggtc gcggcagcat ttgaaggcg tcatactggc ttgcgtcta 360
 ttgcgtatc gctcgatggt cgtcaacatt ttgaaacggc ggcgcgtg gtatgcgatt 420
 tggtccgaa attacacgcc caattattag gcaaacacga aattctgaat attaacgtgc 480
 ccgatgtgcc ttacgaagaa ctgaaaggca ttaaagtgtg ccatttggc taccgttctt 540
 ccgcttctga agtGattaaa cagcaaagcc cgcgtggcga agacatgtat tggatc 596

<210> 13
<211> 429
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<400> 13
gatctgccgt tggcgaaccc ttacgaaatg ctgatcctcg cgtccatcg ggaaaaagaa 60
accggcattt ctcagaacg cccacaagtgc gctcggtat tcattaatcg gttaaaagcc 120
aaaatgaagc tgcaaaaccga tccgaccgtc attacggca tgggcgacga ctacaacggc 180
aatattcgca aaaaagattt gaaacgcca acgccttata acacctatgt gattgacggc 240
ttgcccggcga caccgattgc gatgccgagt gaagaggcg tacaggcggt ggcacatccg 300
gcccggcga cgttttatta ttcgtggca gacggcacgg ggggacacaa attcagtcgt 360
aatttaaacg aacataacaa agcggtgcaag caatattgc gctggtaccg cgaacaaaac 420
ggaaaaataaa 429

<210> 14
<211> 162
<212> DNA
<213> *Actinobacillus actinomycetemcomitans*

<400> 14
atggtaggca aatttattgt cattgaaggc ttggaaggcg caggcaaaag caccgctcat 60
caatgcgttgc gatgatcgat aaaaacgtt ggttgggg aagtcatctc taccggcgg 120
ccgggcggca cacccgttgg cgaaaaagct acgcctatctc at 162

<210> 15
<211> 67
<212> PRT
<213> *Actinobacillus actinomycetemcomitans*

<400> 15
Glu Lys Lys Pro Glu Ala Ala Pro Ala Asp Lys Pro Ala Ala Glu Ala
1 5 10 15

Pro Ala Thr Ile Lys Val Gly Val Met Ala Gly Pro Glu His Gln Val
20 25 30

Ala Glu Ile Ala Ala Lys Val Ala Lys Glu Lys Tyr Asn Leu Asp Val
35 40 45

Glu Tyr Val Leu Phe Met Thr Thr Pro Cys Gln Thr Leu Gln Cys Leu
50 55 60

Lys Val Ile
65

<210> 16
<211> 85
<212> PRT
<213> *Actinobacillus actinomycetemcomitans*

<400> 16

Ile Lys Leu Val Ala Gln Gly Gln Arg Val Ala Asn Leu Pro Asp Ile
1 5 10 15

Leu Val Tyr Ala Arg Val Gly Asn Gly Met Val Gly Arg Arg Arg Gly
20 25 30

Leu Asn Gln Ala Lys Ala Glu Trp Arg Leu Phe Lys Leu Lys His His
35 40 45

Leu Gly Ile Gln Gly Phe Leu Ser Gly Leu Phe Thr Phe Val Leu Arg
50 55 60

Ser Gly Ala Arg Leu Leu Pro Thr Ser Leu Leu Lys Asn Ile Tyr Gln
65 70 75 80

Thr Phe Leu Arg Lys
85

<210> 17

<211> 152

<212> PRT

<213> *Actinobacillus actinomycetemcomitans*

<400> 17

Asp Arg Asn Lys Arg Ser Phe Tyr Ile Ser Ala Ala Arg Ser Glu Ile
1 5 10 15

Phe Asn Leu Ile Val Ala Lys Arg Ile Glu Leu Ser Leu Ala Gln Gln
20 25 30

Val Leu Asn Gly Asp Val Leu Gln Leu Asn Gly Ser His Ser Trp Phe
35 40 45

Val Ala Asp Ala Ser Glu Asp Leu Thr Gln Leu Gln Gln Arg Leu Ala
50 55 60

Gln Arg Asp Ile Leu Leu Thr Ala Pro Leu Ile Gly Glu Glu Asp Lys
65 70 75 80

Ser Ala Val Asp Phe Glu Asn Glu Ile Phe Val Ala His Gln Ala Leu
85 90 95

Phe His Leu Met Arg Gln Glu Arg Val Lys Ala Ala Arg Arg Pro Ile
100 105 110

Leu Met Gln Ala Gln Gln Phe Gln Trp Gln Phe Glu Pro Asn Gly Leu
115 120 125

Arg Leu Lys Phe Tyr Leu Pro Ala Gly Ser Tyr Ala Thr Ala Leu Val
130 135 140

Arg Glu Leu Val Asn Val Glu Asn
145 150

<210> 18

<211> 198

<212> PRT

<213> *Actinobacillus actinomycetemcomitans*

<220>
<221> UNSURE
<222> (43)
<223> Xaa stands for any amino acid.

<220>
<221> UNSURE
<222> (50)
<223> Xaa stands for any amino acid.

<220>
<221> UNSURE
<222> (59)
<223> Xaa stands for any amino acid.

<220>
<221> UNSURE
<222> (66)
<223> Xaa stands for any amino acid.

<220>
<221> UNSURE
<222> (69)
<223> Xaa stands for any amino acid.

<400> 18
Met Asn Ile Leu Leu Ser Asn Asp Asp Gly Ile His Ala Pro Gly Ile
1 5 10 15

Arg Val Met Arg Thr Leu Arg Lys Ile Ala Asn Val Thr Ile Val Ala
20 25 30

Pro Asp Ser Asn Arg Lys Arg Arg Leu Gln Xaa Leu Asn Leu Gly Glu
35 40 45

Ala Xaa Val Phe Arg Ser Phe Gly Lys Ala Xaa Ile Ile Ala Ser Thr
50 55 60

Ala Xaa Pro Ala Xaa Cys Val His Ile Ala Leu Thr Gly Phe Leu Ser
65 70 75 80

Gly Arg Ile Asp Leu Val Ile Ser Gly Ile Asn Ala Gly Ala Asn Leu
85 90 95

Gly Asp Asp Val Leu Tyr Ser Gly Thr Val Ala Ala Ala Phe Glu Gly
100 105 110

Arg His Leu Gly Leu Pro Ser Ile Ala Val Ser Leu Asp Gly Arg Gln
115 120 125

His Phe Glu Thr Ala Ala Arg Val Val Cys Asp Leu Val Pro Lys Leu
130 135 140

His Ala Gln Leu Leu Gly Lys His Glu Ile Leu Asn Ile Asn Val Pro
145 150 155 160

Asp Val Pro Tyr Glu Glu Leu Lys Gly Ile Lys Val Cys His Leu Gly
165 170 175

Tyr Arg Ser Ser Ala Ser Glu Val Ile Lys Gln Gln Ser Pro Arg Gly
180 185 190

Glu Asp Met Tyr Trp Ile
195

<210> 19
<211> 142
<212> PRT
<213> *Actinobacillus actinomycetemcomitans*

<400> 19
Asp Leu Pro Leu Ala Asn Pro Tyr Glu Met Leu Ile Leu Ala Ser Ile
1 5 10 15

Val Glu Lys Glu Thr Gly Ile Ala Ala Glu Arg Pro Gln Val Ala Ser
20 25 30

Val Phe Ile Asn Arg Leu Lys Ala Lys Met Lys Leu Gln Thr Asp Pro
35 40 45

Thr Val Ile Tyr Gly Met Gly Asp Asp Tyr Asn Gly Asn Ile Arg Lys
50 55 60

Lys Asp Leu Glu Thr Pro Thr Pro Tyr Asn Thr Tyr Val Ile Asp Gly
65 70 75 80

Leu Pro Pro Thr Pro Ile Ala Met Pro Ser Glu Glu Ala Leu Gln Ala
85 90 95

Val Ala His Pro Ala Gln Thr Ala Phe Tyr Tyr Phe Val Ala Asp Gly
100 105 110

Thr Gly Gly His Lys Phe Ser Arg Asn Leu Asn Glu His Asn Lys Ala
115 120 125

Val Gln Gln Tyr Leu Arg Trp Tyr Arg Glu Gln Asn Gly Lys
130 135 140

<210> 20
<211> 54
<212> PRT
<213> *Actinobacillus actinomycetemcomitans*

<400> 20
Met Val Gly Lys Phe Ile Val Ile Glu Gly Leu Glu Gly Ala Gly Lys
1 5 10 15

Ser Thr Ala His Gln Cys Val Val Asp Thr Leu Lys Thr Leu Gly Val
20 25 30

Gly Glu Val Ile Ser Thr Arg Glu Pro Gly Gly Thr Pro Val Gly Gly
35 40 45

Lys Ala Thr Pro Ser His
50

09/980,845

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 February 2001 (15.02.2001)

PCT

(10) International Publication Number
WO 01/011081 A3

(51) International Patent Classification⁷: C12Q 1/68.

G01N 33/569

(74) Agent: HILLMAN, Lisa; McDonnell Boehnen Hulbert & Berghoff, 32nd floor, 300 South Wacker Drive, Chicago, IL 60606 (US).

(21) International Application Number: PCT/US00/21340

(22) International Filing Date: 4 August 2000 (04.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/147,551 6 August 1999 (06.08.1999) US

(71) Applicant (*for all designated States except US*): IVI-GENE CORPORATION [US/US]; 12085 Research Drive, Alachua, FL 32615 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): PROGULSKE-FOX, Ann [US/US]; 6392 Country Road 214 S, Key-stone Heights, FL 32656 (US). HANDFIELD, Martin [CA/US]; 2001 SW 16th Street #E-5, Gainesville, FL 32608 (US). BRADY, L., Jeannine [US/US]; 13214 NW County Rd. 231, Gainesville, FL 32609 (US). HILLMAN, Jeffrey, D. [US/US]; 6424 SW 26th Place, Gainesville, FL 32608 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
11 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/011081 A3

(54) Title: MICROBIAL POLYNUCLEOTIDES EXPRESSED DURING INFECTION OF A HOST

(57) Abstract: The invention provides methods useful for identifying polynucleotides expressed *in vivo* by a microbe during infection of a host. Antibodies against antigens that are expressed by the microbe *in vivo* and *in vitro* are adsorbed with cells or cellular extracts of the microbe that have been grown *in vitro*. Unadsorbed antibodies are isolated and are probed against an expression library of the microbe's DNA. A polynucleotide of the microbe that is expressed *in vivo* is isolated and identified.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/21340

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C12Q1/68 G01N33/569

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 30910 A (SCHERER PHILIPP E ;WHITEHEAD BIOMEDICAL INST (US); BICKEL PERRY E) 16 July 1998 (1998-07-16) the whole document ---	1-17
Y	SUK KYOUNGHO ET AL: "Borrelia burgdorferi genes selectively expressed in the infected host." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 92, no. 10, 1995, pages 4269-4273, XP002184771 1995 ISSN: 0027-8424 the whole document ---	1-17 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

5 December 2001

20/12/2001

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
 Fax: (+31-70) 340-3016

Authorized officer

Reuter, U

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/21340

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 05293 A (SINAI SCHOOL MEDICINE ;FLISS MAKIKO (US); BANCROFT FRANK C (US)) 4 February 1999 (1999-02-04) page 1-2 page 15; claims; figure 1 ---	1-17
A	WO 98 46738 A (BARNES JEWISH HOSPITAL) 22 October 1998 (1998-10-22) the whole document ---	1-17
A	WO 99 32633 A (MILHAUSEN MICHAEL JAMES ;HESKA CORP (US); NG RAY K (US); LUTZ SUSA) 1 July 1999 (1999-07-01) page 34; example 5 page 2-3; example 2 ---	1-17
A	HANDFIELD M ET AL: "STRATEGIES FOR ISOLATION OF IN VIVO EXPRESSED GENES FROM BACTERIA" FEMS MICROBIOLOGY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 23, no. 1, January 1999 (1999-01), pages 69-91, XP002929895 ISSN: 0168-6445 cited in the application the whole document -----	1-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/21340

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
WO 9830910	A 16-07-1998	AU WO	6240198 A 9830910 A1	03-08-1998 16-07-1998
WO 9905293	A 04-02-1999	US AU WO	6040144 A 8658798 A 9905293 A1	21-03-2000 16-02-1999 04-02-1999
WO 9846738	A 22-10-1998	AU WO	7128098 A 9846738 A1	11-11-1998 22-10-1998
WO 9932633	A 01-07-1999	AU WO US	1934899 A 9932633 A1 2001014447 A1	12-07-1999 01-07-1999 16-08-2001

PATENT COOPERATION TREATY

PCT

09980.845

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference MBHB00-505	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 21340	International filing date (day/month/year) 04/08/2000	(Earliest) Priority Date (day/month/year) 06/08/1999
Applicant IVIGENE CORPORATION et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).
- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :
 - contained in the international application in written form.
 - filed together with the international application in computer readable form.
 - furnished subsequently to this Authority in written form.
 - furnished subsequently to this Authority in computer readable form.
 - the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
 - the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. **Certain claims were found unsearchable** (See Box I).

3. **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

- the text is approved as submitted by the applicant.
- the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

- the text is approved as submitted by the applicant.
- the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

- as suggested by the applicant.
- because the applicant failed to suggest a figure.
- because this figure better characterizes the invention.

None of the figures.